UCSF researchers designed new drug candidates that potently block MPro, a viral enzyme that's crucial for SARS-CoV-2 replication. One of these drug candidates, AVI-4516, is shown (center) bound to the ...

"This community prevalence study, conducted during the peak of the COVID-19 pandemic after the emergence of Omicron variants, confirmed that a large proportion of SARS-CoV-2 infections were either ...

Hospitalised adults with SARS‑CoV‑2, parainfluenza virus, or respiratory syncytial virus (RSV) infection are more likely to develop acute respiratory failure than those with influenza A/B infection — ...

Since the start of the COVID-19 pandemic, there has been controversy surrounding the origins of SARS-CoV-2. New research from the University of California, San Diego (UCSD), School of Medicine ...